For the study, international researchers reviewed 245 academic articles from 46 countries to analyze the scale of COVID-19’s disruption on cancer care.
Here are four notes from their analysis:
- In addition to the 39% decline in cancer screening, diagnostic procedures declined by 24% and cancer diagnoses declined by 23% compared to prepandemic levels.
- Cancer treatment declined by 28% overall, with a 15% decline in radiotherapy treatment and a 35% decline in systemic treatment, compared to prepandemic levels.
- Countries with high and very high human-development indexes experienced fewer cancer care reductions compared to countries with medium human-development indexes, while cancer care data from countries with low human-development indexes were “missing,” study authors wrote.
- A different, recent study analyzed how the COVID-19 pandemic influenced cancer incidence rates. Between January 2020 and December 2021, the cancer incidence rate in the U.S. was 6% lower than expected, equating to 149,577 potentially missed diagnoses.
Read the full study here.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
